Institutional Repository UDD

Low- versus standard-dose alteplase in patients on prior antiplatelet therapy: the ENCHANTED trial (enhanced control of hypertension and thrombolysis stroke study)

Show simple item record Robinson, Thompson G. Wang, Xia Arima, Hisatomi Bath, Philip Billot, Laurent Broderick, Joseph P. Demchuk, Andrew M. Donnan, Geoffery A. Kim, Jong S. Lavados, Pablo Lee, Tsong-Hai Lindley, Richard I. Martins, Sheila C. O. Olavarria, Veronica V. Pandian, Jeyaraj D. Parsons, Mark W. Pontes-Neto, Octavio M. Ricci, Stefano Sato, Shoichiro Sharma, Vijay K. Nguyen, Thang H. Wang, Ji-Guang Woodward, Mark Chalmers, John Anderson, Craig ENCHANTED Investigators 2017-09-12T13:04:14Z 2017-09-12T13:04:14Z 2017
dc.identifier.citation Stroke. 2017 Jul;48(7):1877-1883 es_CL
dc.identifier.uri es_CL
dc.description.abstract BACKGROUND AND PURPOSE: Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study). METHODS: Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior APT use. Primary outcome at 90 days was the combined end point of death or disability (modified Rankin Scale [mRS] scores, 2-6). Other outcomes included mRS scores 3 to 6, ordinal mRS shift, and symptomatic intracerebral hemorrhage by various standard criteria. RESULTS: There were no significant differences in outcome between patients with and without prior APT after adjustment for baseline characteristics and management factors during the first week; defined by mRS scores 2 to 6 (adjusted odds ratio [OR], 1.01; 95% confidence interval [CI], 0.81-1.26; P=0.953), 3 to 6 (OR, 0.95; 95% CI, 0.75-1.20; P=0.662), or ordinal mRS shift (OR, 1.03; 95% CI, 0.87-1.21; P=0.770). Alteplase-treated patients on prior APT had higher symptomatic intracerebral hemorrhage (OR, 1.82; 95% CI, 1.00-3.30; P=0.051) according to the safe implementation of thrombolysis in stroke-monitoring study definition. Although not significant (P-trend, 0.053), low-dose alteplase tended to have better outcomes than standard-dose alteplase in those on prior APT compared with those not using APT (mRS scores of 2-6; OR, 0.84; 95% CI, 0.62-1.12 versus OR, 1.16; 95% CI, 0.99-1.36). CONCLUSIONS: Low-dose alteplase may improve outcomes in thrombolysis-treated acute ischemic stroke patients on prior APT, but this requires further evaluation in a randomized controlled trial. es_CL
dc.format.extent 7 es_CL
dc.language.iso en_US es_CL
dc.publisher American Heart Association es_CL
dc.subject aspirin es_CL
dc.subject brain infarction es_CL
dc.subject hypertension es_CL
dc.subject intracranial hemorrhages es_CL
dc.subject tissue plasminogen activator es_CL
dc.title Low- versus standard-dose alteplase in patients on prior antiplatelet therapy: the ENCHANTED trial (enhanced control of hypertension and thrombolysis stroke study) es_CL
dc.type Artículo es_CL

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account